Cargando…
Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288996/ https://www.ncbi.nlm.nih.gov/pubmed/28184256 http://dx.doi.org/10.1186/s13148-017-0316-8 |
_version_ | 1782504434769592320 |
---|---|
author | Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Wiemels, Joseph L. Roy, Ritu P. Hansen, Helen M. Rice, Terri McCoy, Lucie S. Bracci, Paige M. Molinaro, Annette M. Kelsey, Karl T. Wrensch, Margaret R. Christensen, Brock C. |
author_facet | Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Wiemels, Joseph L. Roy, Ritu P. Hansen, Helen M. Rice, Terri McCoy, Lucie S. Bracci, Paige M. Molinaro, Annette M. Kelsey, Karl T. Wrensch, Margaret R. Christensen, Brock C. |
author_sort | Wiencke, John K. |
collection | PubMed |
description | BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors. We first estimated the proportions of leukocyte subtypes in samples using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. Then, we calculated the neutrophil to lymphocyte ratio (NLR) using methylation-derived cell composition estimates (mdNLR). The NLR is considered an indicator of immunosuppressive cells in cancer patients. RESULTS: Elevated mdNLR scores were observed in glioma patients compared to mdNLR values of published controls. Significantly decreased survival times were associated with mdNLR ≥ 4.0 in Cox proportional hazards models adjusted for age, gender, tumor grade, and molecular subtype (HR 2.02, 95% CI, 1.11–3.69). We also identified five myeloid-related CpGs that were highly correlated with the mdNLR (adjusted R (2) ≥ 0.80). Each of the five myeloid CpG loci was associated with survival when adjusted for the above covariates and offer a simplified approach for utilizing fresh or archived peripheral blood samples for interrogating a very small number of methylation markers to estimate myeloid immune influences in glioma survival. CONCLUSIONS: The mdNLR (based on DNA methylation) is a novel candidate methylation biomarker that represents immunosuppressive myeloid cells within the blood of glioma patients with potential application in clinical trials and future epidemiologic studies of glioma risk and survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0316-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5288996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52889962017-02-09 Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Wiemels, Joseph L. Roy, Ritu P. Hansen, Helen M. Rice, Terri McCoy, Lucie S. Bracci, Paige M. Molinaro, Annette M. Kelsey, Karl T. Wrensch, Margaret R. Christensen, Brock C. Clin Epigenetics Research BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors. We first estimated the proportions of leukocyte subtypes in samples using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. Then, we calculated the neutrophil to lymphocyte ratio (NLR) using methylation-derived cell composition estimates (mdNLR). The NLR is considered an indicator of immunosuppressive cells in cancer patients. RESULTS: Elevated mdNLR scores were observed in glioma patients compared to mdNLR values of published controls. Significantly decreased survival times were associated with mdNLR ≥ 4.0 in Cox proportional hazards models adjusted for age, gender, tumor grade, and molecular subtype (HR 2.02, 95% CI, 1.11–3.69). We also identified five myeloid-related CpGs that were highly correlated with the mdNLR (adjusted R (2) ≥ 0.80). Each of the five myeloid CpG loci was associated with survival when adjusted for the above covariates and offer a simplified approach for utilizing fresh or archived peripheral blood samples for interrogating a very small number of methylation markers to estimate myeloid immune influences in glioma survival. CONCLUSIONS: The mdNLR (based on DNA methylation) is a novel candidate methylation biomarker that represents immunosuppressive myeloid cells within the blood of glioma patients with potential application in clinical trials and future epidemiologic studies of glioma risk and survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0316-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-02 /pmc/articles/PMC5288996/ /pubmed/28184256 http://dx.doi.org/10.1186/s13148-017-0316-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Wiemels, Joseph L. Roy, Ritu P. Hansen, Helen M. Rice, Terri McCoy, Lucie S. Bracci, Paige M. Molinaro, Annette M. Kelsey, Karl T. Wrensch, Margaret R. Christensen, Brock C. Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title | Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title_full | Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title_fullStr | Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title_full_unstemmed | Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title_short | Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival |
title_sort | immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (nlr) in glioma survival |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288996/ https://www.ncbi.nlm.nih.gov/pubmed/28184256 http://dx.doi.org/10.1186/s13148-017-0316-8 |
work_keys_str_mv | AT wienckejohnk immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT koestlerdevinc immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT salaslucasa immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT wiemelsjosephl immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT royritup immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT hansenhelenm immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT riceterri immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT mccoylucies immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT braccipaigem immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT molinaroannettem immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT kelseykarlt immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT wrenschmargaretr immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival AT christensenbrockc immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival |